RANCHO CUCAMONGA, CA / ACCESS WIRE / October 28, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its 2022 third quarter ended September 30, 2022, after market close on Monday, November 7, 2022, and will hold a conference call to discuss its financial results at 2:00 a.m. a.m. Pacific Time.

To access the conference call, dial toll-free (877) 407-0989, for international calls, dial (201) 389-0921, five minutes before the conference call.

The call is also available on the Investors page of the Company’s website. www.ampastar.com.

Company information

Amphastar is a biopharmaceutical company primarily focused on the development, manufacturing, marketing and sale of technically challenging generic and proprietary injectable, inhalation and intranasal products. Additionally, the Company sells insulin API products. Most of the Company’s finished products are used in hospitals or urgent care clinics and are mainly contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.ampastar.com.

Forward-looking statements

All statements in this press release that are not historical are forward-looking statements. These statements are not historical facts but rather are based on Amphastar’s historical performance and its current expectations, estimates and projections regarding Amphastar’s business, operations and other similar or related factors. Words such as “may”, “could”, “will”, “could”, “should”, “should”, “anticipate”, “predict”, “potential”, “continue”, “expect” , “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements as they involve known and unknown risks, uncertainties and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar’s control.Actual results may differ materially from those in the forward-looking statements due to a number of factors, including those described in Amphastar’s filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on March 11, 2022. You can find these reports on the Company’s website at http://ir.ampastar.com and on the SEC’s website at the address www.sec.gov. The forward-looking statements contained in this press release speak only as of the date of the press release. Amphastar undertakes no obligation to revise or update any information or forward-looking statements contained in this press release to reflect future events or circumstances, even if new information becomes available or if subsequent events change Amphastar’s expectations.

Contact:
Bill Peters
Financial director
(909) 476-3416

THE SOURCE: Amphastar Pharmaceuticals, Inc.

See the source version on accesswire.com:

https://www.accesswire.com/722706/Amphastar-Pharmaceuticals-to-Release-Third-Quarter-Earnings-and-Hold-Conference-Call-on-November-7-2022

WALTHAM, Mass., Oct. 27, 2022 /PRNewswire/ — Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will report third quarter 2022 financial results and provide a business update on Thursday, November 3. after the end of the US fiscal year. markets.

In connection with the earnings release, Syndax management will host a conference call and live audio webcast at 4:30 p.m. ET on Thursday, November 3, 2022 to discuss the Company’s financial results and provide a business update.

The live audio webcast and accompanying slides can be accessed via the Events and presentations page in the Investors section of the Company’s website. Alternatively, the conference call can be accessed by the following means:

Conference ID: SYNDAXQ3
National hotline: 800-225-9448
International dial-in number: 203-518-9708
Live webcast: https://www.veracast.com/webcasts/OpenEx/General/S03S7x.cfm

For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company’s website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days after the call.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company’s pipeline highlights include revumenib (SNDX-5613), a highly selective inhibitor of the Menin-MLL binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1), both currently in pivotal trials. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.

Contact Syndax

Sharon Klahre
Syndax Pharmaceuticals, Inc.
[email protected]
Tel 781.684.9827

SNDX-G

Show original content:https://www.prnewswire.com/news-releases/syndax-to-announce-third-quarter-2022-financial-results-and-host-conference-call-and-webcast-on-november-3-2022- 301660461.html

SOURCE Syndax Pharmaceuticals, Inc.

Company Codes: NASDAQ-NMS:SNDX

(TSX: KBL)

EDMONTON, Alta., October 27, 2022 /CNW/ – K-Bro Linen Inc. (the “Company”) will publish its financial results for the quarter ended September 30, 2022 on Wednesday, November 9, 2022 after market close. The Company will hold a conference call and webcast to discuss the results on Thursday, November 10, 2022 at 8:00 a.m. Eastern Time (6:00 a.m. Mountain Time).

The conference call will include remarks prepared by Linda McCurdyPresident and CEO, and Kristie Plaquin, Financial director. After prepared remarks, the Company will accept questions from analysts and institutional investors.

Participants are requested to call at least 10 minutes before the start of the call. For those unable to participate in the live call, a replay will be available until November 17, 2022 by dialing 1.888.203.1112 (Canada and UNITED STATES), access code 7035685. The public is invited to listen to the conference call live or the replay.

This conference call will be webcast live and available to all interested parties at the following addresses:
https://app.webinar.net/6zwomeymGPD

To listen to the live webcast, visit the Company’s website at least 10 minutes in advance to register, download and install any necessary audio software. For those unable to listen during the live webcast, an audio replay will be available shortly after the conference call ends for a period of 90 days.

COMPANY PROFILE

K-Bro is the largest owner and operator of laundry and linen processing facilities in Canada. K-Bro provides a full range of general linen and operating room linen processing, management and distribution services to healthcare facilities, hotels and other commercial accounts. K-Bro currently operates nine processing facilities under three distinct brands, including K-Bro Laundry Systems Inc.Buanderie HMR and Les Buanderies Dextraze, in eight Canadian cities: Quebec City, Montreal, TorontoRegina, Edmonton, Calgary, Vancouver and Victoria.

Fishers was founded in 1900 and operates laundry and linen processing facilities in Scotland, providing linen, workwear and cleanroom apparel rental services to the hospitality, healthcare, manufacturing and pharmaceutical industries. Fishers customer base includes major hotel chains and prestigious venues across Scotland and the northeast of England. The company operates seven sites, including a depot, at Scotland and the northeast of England with facilities in To cut, Perth, NewcastleLivingston and Coatbridge.

Additional information regarding the company, including required securities filings, is available on our website at www.k-brolinen.com and on the website of the Canadian Securities Administrators at www.sedar.com; the System for Electronic Document Analysis and Retrieval (“SEDAR”).

K‑Bro is the largest laundry owner and operator in the Canada. K‑Bro provides a wide range of laundry services to healthcare facilities, hotels and other commercial customers. K‑Bro currently operates nine factories under three distinctive brands, including K-Bro Laundry Systems Inc.Buanderie HMR and Les Buanderies Dextraze, in eight Canadian cities: Quebec, Montreal, TorontoRegina, Edmonton, Calgary, Vancouver and Victoria.

Additional information about the Company, including filings with regulatory authorities, is available on our website at www.k-brolinen.com and on the website of the Canadian Securities Administrators at www.sedar. com, the System for Electronic Document Analysis and Retrieval (“SEDAR”) website.

THE SOURCE K-Bro Linen Inc.

© Canada Newswire, source Canada Newswire English

---

Enter Wall Street with StreetInsider Premium. Claim your one week free trial here.

---

St. Louis, Oct. 25, 2022 (GLOBE NEWSWIRE) — ESCO Technologies Inc. (NYSE: SEA) will release its fourth quarter and full year financial results after market close on Thursday, November 17, 2022, followed by a conference call in which the financial results and related commentary will be discussed.

Event: Q4 2022 Conference Call
When: Thursday, November 17
Time: 4:00 p.m. Central Time

The webcast of the conference call and an accompanying slide presentation will be available on ESCO’s Investors website at https://investor.escotechnologies.com. The slide presentation will be used during the call and will be posted on the website prior to the call. Participants can also access the webcast using this registration link.

For those unable to attend, a replay of the webcast will be available after the call on the Company’s Investors website.

ESCO is a global provider of highly technical products and solutions for various end markets. It manufactures filtration and fluid control products for the global aviation, marine, space and process markets, as well as composite-based products and solutions for marine, defense and industry. ESCO is the industry leader in RF shielding and EMC test products; and provides diagnostic instruments, software and services to industrial electricity users and the electric utility and renewable energy industries. Headquartered in St. Louis, Missouri, ESCO and its subsidiaries have offices and manufacturing facilities around the world. For more information about ESCO and its affiliates, visit the company’s website at www.escotechnologies.com.

SOURCEESCO Technologies Inc.
Kate Lowrey, Vice President of Investor Relations, (314) 213-7277

# # #

SANTA CLARA, Calif.–(BUSINESS WIRE)– Heart Beam, Inc.. (NASDAQ: BEAT), a cardiac technology company that developed the first and only 3D vector ECG platform for anytime, anywhere heart attack detection, will hold a conference call on Thursday, November 10, 2022 at 4 p.m. 30:30 a.m. Eastern Time to discuss its results for the third quarter ended September 30, 2022, and will review recent announcements, ongoing initiatives and key milestones for 2022 and planned for 2023. A press release detailing these results will be published before the call.

HeartBeam CEO and Founder Branislav Vajdic, PhD, CFO Richard Brounstein, and CBO Jon Hunt, PhD, will host the conference call, followed by a Q&A.; The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the Investor Relations section of the Company’s website. here.

To access the call, please use the following information:

A telephone replay will be available approximately two hours after the call and will continue through February 10, 2023 by dialing 1-844-512-2921 from the United States or 1-412-317-6671 from international destinations and by entering the replay PIN. : 7787050. The replay can also be viewed via the webcast link above and the presentation used in the call will be available in the company’s investor relations section. here.

About HeartBeam, Inc.

HeartBeam, Inc. (NASDAQ: BEAT) is a heart technology company that has developed the first and only 3D vector ECG platform for anytime, anywhere heart attack detection. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to quickly and easily determine if symptoms are due to a heart attack, so care can be expedited. , if necessary. HeartBeam has two patented products in development. HeartBeam AIMI™ is software for acute care settings that provides 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo™ is the first and only credit card-sized 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to aid in remote heart attack detection . HeartBeam AIMI and AIMIGo have not yet been cleared by the United States Food and Drug Administration (FDA) for marketing in the United States or other geographies. For more information, visit HeartBeam.com.

Forward-looking statements

All statements in this release that are not based on historical fact are “forward-looking statements.” Although management has based the forward-looking statements included in this release on its current expectations, the information on which these expectations were based may change. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those contained in the forward-looking statements due to a variety of factors, including the risks and uncertainties described in the Risk Factors and in the management report of the financial situation. The Trading Status and Results sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider these risks and uncertainties when evaluating our forward-looking statements. We caution readers not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by federal securities laws, we disclaim any obligation or undertaking to release any updates or revisions to any forward-looking statements contained herein (or elsewhere) to reflect any changes in our expectations with respect thereto. or any change of events. , conditions or circumstances on which such statement is based.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20221025005427/en/

GOTHENBURG, SE / ACCESS WIRE / October 21, 2022 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL) (FRA:3XV) Invitation to participate in XVIVO’s conference call regarding the presentation of the January-September 2022 interim report. The presentation will be held in English.

Time: Thursday, October 27 at 2:00 p.m. CET

To join the conference call from your computer, use the following link:

https://onlineexperiences.com/Launch/QReg/ShowUUID=DC9EC0A8-A38E-4EAD-A1E0-7C962D4BB5FD

Conference phone numbers:
Sweden: +46 856642651 PIN: 82398789#
UK: +44 3333000804 PIN: 82398789#
USA: +1 6319131422 PIN: 82398789#
Conference name: XVIVO Interim Report Q3 2022

XVIVO Participants:
Christoffer Rosenblad, interim CEO
Kristoffer Nordström, CFO

The press release for the XVIVO January-September 2022 interim report will be published on October 27, 2022 at 7:30 a.m. CET.

Prior to the conference call, slides will be available on the company’s webpage, https://www.xvivoperfusion.com/corporate/financial-presentations/earnings-calls/

October 21, 2022
Gothenburg
XVIVO Infusion AB (publ)

For more information, please contact:

Christoffer Rosenblad, Acting CEO, +46 73 519 21 59, email: [email protected]
Kristoffer Nordström, CFO, +46 73 519 21 64, email: [email protected]

About Us

Founded in 1998, XVIVO is the only medical technology company dedicated to extending the lifespan of all major organs – so that transplant teams around the world can save more lives. Our solutions enable leading clinicians and researchers to push the boundaries of transplant medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and bears the symbol XVIVO. More information can be found at www.xvivogroup.com.

Attachments

Interim Report Conference Call

THE SOURCE: XVIVO Infusion AB

See the source version on accesswire.com:

https://www.accesswire.com/721546/Conference-Call-on-Interim-Report

Civeo Corporation (NYSE:CVEO) announced today that it has scheduled its third quarter 2022 earnings conference call for Friday, October 28 at 10:00 a.m. Central Time (11:00 a.m. Eastern). During the call, Civeo will discuss third quarter 2022 financial and operational results, which will be released prior to market open on Friday, October 28, 2022.

By telephone:

Dial 877-423-9813 in the US or 201-689-8573 internationally and request the Civeo call or provide the conference ID: 13733925# at least 10 minutes before the start time.

A replay will be available through November 4 by dialing 844-512-2921 in the United States or 412-317-6671 internationally and using conference ID 13733925#.

By Webcast:

Connect to the webcast via the Events and Presentations page of Civeo’s Investor Relations site at www.civeo.com.

Please log in at least 10 minutes in advance to register and download any necessary software.

A replay of the webcast will be available after the call.

ABOUT CIVEO

Civeo Corporation is a leading hospitality service provider with leading positions in the Canadian oil sands and Australian natural resource regions markets. Civeo offers complete solutions to house hundreds or thousands of workers with its long-term and temporary housing and provides catering, housekeeping, facilities management, laundry, water treatment and cleaning services. wastewater, power generation, communication systems, security and logistics services. Civeo currently owns and operates a total of 27 lodges and villages in Canada, Australia and the United States, with a total of over 28,000 rooms. Civeo is publicly traded under the symbol CVEO on the New York Stock Exchange. For more information, visit the Civeo website at www.civeo.com.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20221018006274/en/

BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV), today announced that it will host a webcast and conference call to discuss company updates and financial results for its fiscal second quarter, ended September 30, 2022. The webcast and the conference call will take place at 5:00 p.m. Eastern Time. / 2:00 p.m. PT on October 26, 2022.

Investors and the general public can access the live webcast here. The live webcast can also be accessed by visiting the Company’s Investor Relations page on Myovant’s website at: https://investors.myovant.com/.

The webcast will be archived on the company’s website for approximately one year.

ABOUT MYOVANT SCIENCES
Myovant Sciences aspires to redefine care for women and men through goal-oriented science, empowering medicines and transformative advocacy. Founded in 2016, Myovant has completed five Phase 3 clinical trials in oncology and women’s health, leading to three U.S. Food and Drug Administration (FDA) regulatory approvals for men with a advanced prostate cancer, women with heavy menstrual bleeding associated with uterine fibroids, and premenopausal women with moderate to severe pain associated with endometriosis, respectively. Myovant has also received regulatory approvals from the European Commission (EC) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for women with symptomatic uterine fibroids and for men with breast cancer. advanced hormone-responsive prostate. Myovant has an additional New Drug Application under review with the FDA for United States Prescribing Information (USPI) updates based on safety and efficacy data from the withdrawal study Phase 3 LIBERTY (RWS) trial of MYFEMBREE in premenopausal women with heavy menstrual bleeding due to uterine fibroids for up to two years. Myovant is also conducting a phase 3 study to assess pregnancy prevention in women with uterine fibroids or endometriosis. In addition, Myovant is developing MVT-602, an investigational kisspeptin-1 oligopeptide receptor agonist, which has completed a Phase 2a study in female infertility in assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Pharma Co., Ltd., is the majority shareholder of Myovant. For more information, please visit www.myovant.com. Follow @Myovant on Twitter and LinkedIn.

Investor contacts:
Uneek Mehra
Financial and Commercial Director
Myovant Sciences, Inc.

[email protected]

Media Contact:
Noelle Cloud Dugan
Vice President, Corporate Communications
Myovant Sciences, Inc.

[email protected]